thrombocytopenia , and eosinophilia . Rarely, thrombocytopenia , sideroblastic anemia (with erythroid hyperplasia , vacuolation of erythrocytes, and increased serum concentration), and adverse effects on blood clotting mechanisms have been reported with pyrazinamide use. Thrombocytopenia , leukopenia , hemolytic anemia, decreased hemoglobin , and agranulocytosis (rare) have been reported with rifampin use.